Review
Genetic Polymorphisms of OATP Transporters and Their Impact on Intestinal Absorption and Hepatic Disposition of Drugs

https://doi.org/10.2133/dmpk.DMPK-11-RV-099Get rights and content

Summary:

There is convincing evidence that many organic anion transporting polypeptide (OATP) transporters influence the pharmacokinetics and pharmacological efficacy of their substrate drugs. Each OATP family member has a unique combination of tissue distribution, substrate specificity and mechanisms of gene expression. Among them, OATP1B1, OATP1B3 and OATP2B1 have been considered as critical molecular determinants of the pharmacokinetics of a variety of clinically important drugs. Liver-specific expression of OATP1B1 and OATP1B3 contributes to the hepatic uptake of drugs from the portal vein, and OATP2B1 may alter their intestinal absorption as well as hepatic extraction. Accordingly, changes in function and expression of these three OATPs owing to genetic polymorphisms may lead to altered pharmacological effects, including decreased drug efficacy and increased risk of adverse effects. Association of genetic polymorphisms in OATP genes with alterations in the pharmacokinetic properties of their substrate drugs has been reported; however, there still exists a degree of discordance between the reported outcomes in different clinical settings. For better understanding of the clinical relevance of genetic polymorphisms of OATP1B1, OATP1B3 and OATP2B1, the present review focuses on the association of the genotypes of these OATPs with in vitro activity changes and in vivo clinical outcomes of substrate drugs.

References (127)

  • T. Abe et al.

    Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1

    J. Biol. Chem.

    (1999)
  • M. Nakakariya et al.

    Identification and species similarity of OATP transporters responsible for hepatic uptake of beta-lactam antibiotics

    Drug Metab. Pharmacokinet.

    (2008)
  • R.G. Tirona et al.

    Polymorphisms in OATP-C

    J. Biol. Chem.

    (2001)
  • S.-R. Kim et al.

    Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15

    Drug Metab. Pharmacokinet.

    (2007)
  • D. Voora et al.

    The SLCO1B1*5 genetic variant is associated with statin-induced side effects

    J. Am. Coll. Cardiol.

    (2009)
  • K. Morimoto et al.

    A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy

    Drug Metab. Pharmacokinet.

    (2004)
  • T. Abe et al.

    LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers

    Gastroenterology

    (2001)
  • M. Tsujimoto et al.

    Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects

    Drug Metab. Pharmacokinet.

    (2006)
  • M. Tsujimoto et al.

    Influence of SLCO1B3 gene polymorphism on the pharmacokinetics of digoxin in terminal renal failure

    Drug Metab. Pharmacokinet.

    (2008)
  • B. Hsiang et al.

    A novel human hepatic organic anion transporting polypeptide (OATP2)

    J. Biol. Chem.

    (1999)
  • Y. Cui et al.

    Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6

    J. Biol. Chem.

    (2001)
  • M.G. Ismair et al.

    Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver

    Gastroenterology

    (2001)
  • Tamai, I.: Oral drug delivery utilizing intestinal OATP transporters. Adv. Drug Deliv. Rev., in...
  • E. Jacquemin et al.

    Expression cloning of a rat liver Na(+)-independent organic anion transporter

    Proc. Natl. Acad. Sci. USA

    (1994)
  • J. König

    Uptake transporters of the human OATP family [M]

  • A. Tsuji et al.

    Transcellular transport of benzole acid across Caco-2 cells by a pH-dependent and carrier-mediated transport mechanism

    Pharm. Res.

    (1994)
  • I. Tamai et al.

    Proton-cotransport of pravastatin across intestinal brush-border membrane

    Pharm. Res.

    (1995)
  • A. Tsuji et al.

    Carrier-mediated intestinal transport of drugs

    Pharm. Res.

    (1996)
  • I. Tamai et al.

    Intestinal brush-border membrane transport of monocarboxylic acids mediated by proton-coupled transport and anion antiport mechanisms

    J. Pharm. Pharmacol.

    (1997)
  • D. Kobayashi et al.

    Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane

    J. Pharmacol. Exp. Ther.

    (2003)
  • J. König et al.

    A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane

    Am. J. Physiol. Gastrointest. Liver Physiol.

    (2000)
  • B. Gao et al.

    Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier

    J. Pharmacol. Exp. Ther.

    (2000)
  • H. Glaeser et al.

    Intestinal drug transporter expression and the impact of grapefruit juice in humans

    Clin. Pharmacol. Ther.

    (2007)
  • Y. Meier et al.

    Regional distribution of solute carrier mRNA expression along the human intestinal tract

    Drug Metab. Dispos.

    (2007)
  • X. Wang et al.

    Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators

    Drug Metab. Dispos.

    (2005)
  • T. Nozawa et al.

    Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms

    Drug Metab. Dispos.

    (2005)
  • H. Takane et al.

    Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy

    Cancer Chemother. Pharmacol.

    (2009)
  • W. Ni et al.

    Flavopiridol pharmacogenetics: Clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition

    PLoS ONE

    (2010)
  • E. van de Steeg et al.

    Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1)

    Drug Metab. Dispos.

    (2009)
  • D.A. Katz et al.

    Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics

    Clin. Pharmacol. Ther.

    (2006)
  • R.G. Tirona et al.

    Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation

    J. Pharmacol. Exp. Ther.

    (2003)
  • T. Nozawa et al.

    Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele frequencies in the Japanese population and functional analysis

    J. Pharmacol. Exp. Ther.

    (2002)
  • M. Iwai et al.

    Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C)

    Pharmacogenetics

    (2004)
  • Y. Kameyama et al.

    Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells

    Pharmacogenet. Genomics

    (2005)
  • W.M. van der Deure et al.

    Organic anion transporter 1B1: An important factor in hepatic thyroid hormone and estrogen transport and metabolism

    Endocrinology

    (2008)
  • Y. Nishizato et al.

    Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics

    Clin. Pharmacol. Ther.

    (2003)
  • M. Niemi et al.

    High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

    Pharmacogenetics

    (2004)
  • M.K. Pasanen et al.

    Global analysis of genetic variation in SLCOlBl

    Pharmacogenomics

    (2008)
  • J. Mwinyi et al.

    Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics

    Clin. Pharmacol. Ther.

    (2004)
  • K. Maeda et al.

    Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril

    Clin. Pharmacol. Ther.

    (2006)
  • Cited by (108)

    • Mathematical modeling analysis of hepatic uric acid disposition using human sandwich-cultured hepatocytes

      2020, Drug Metabolism and Pharmacokinetics
      Citation Excerpt :

      Although we preliminary observed OATP2B1-mediated transport of uric acid (unpublished observation), at present there is no clear reports about uric acid transport by OATPs. Since OATPs, such as OATP1B1, 1B3 and 2B1, are functional at sinusoidal membrane of hepatocytes [38], further study on OATP-mediated transport of uric acid is required. It is not clear why these transporters may have different contribution to uric acid efflux.

    View all citing articles on Scopus
    View full text